Oncolytic virotherapy in cancer treatment: challenges and optimization prospects

Lingjuan Chen; Lingjuan Chen; Lingjuan Chen; Mengsi Zuo; Qin Zhou; Yang Wang

doi:10.3389/fimmu.2023.1308890

Frontiers in Immunology (Dec 2023)

Oncolytic virotherapy in cancer treatment: challenges and optimization prospects

Lingjuan Chen,
Lingjuan Chen,
Lingjuan Chen,
Mengsi Zuo,
Qin Zhou,
Yang Wang

Affiliations

Lingjuan Chen: Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Lingjuan Chen: Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Lingjuan Chen: Hubei Key Laboratory of Precision Radiation Oncology, Wuhan, China
Mengsi Zuo: Department of Oncology, The Sixth Hospital of Wuhan, Affiliated Hospital of Jianghan University, Wuhan, China
Qin Zhou: National “111” Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering (Ministry of Education), Cooperative Innovation Center of Industrial Fermentation (Ministry of Education & Hubei Province), College of Bioengineering, Hubei University of Technology, Wuhan, China
Yang Wang: National “111” Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering (Ministry of Education), Cooperative Innovation Center of Industrial Fermentation (Ministry of Education & Hubei Province), College of Bioengineering, Hubei University of Technology, Wuhan, China

DOI: https://doi.org/10.3389/fimmu.2023.1308890
Journal volume & issue: Vol. 14

Abstract

Read online

Oncolytic viruses (OVs) are emerging cancer therapeutics that offer a multifaceted therapeutic platform for the benefits of replicating and lysing tumor cells, being engineered to express transgenes, modulating the tumor microenvironment (TME), and having a tolerable safety profile that does not overlap with other cancer therapeutics. The mechanism of OVs combined with other antitumor agents is based on immune-mediated attack resistance and might benefit patients who fail to achieve durable responses after immune checkpoint inhibitor (ICI) treatment. In this Review, we summarize data on the OV mechanism and limitations of monotherapy, which are currently in the process of combination partner development, especially with ICIs. We discuss some of the hurdles that have limited the preclinical and clinical development of OVs. We also describe the available data and provide guidance for optimizing OVs in clinical practice, as well as a summary of approved and promising novel OVs with clinical indications.

Published in Frontiers in Immunology

ISSN: 1664-3224 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Website: http://journal.frontiersin.org/journal/immunology

About the journal

Abstract

Keywords